Sometimes?

Animal studies and other data tracking the effects of reducing the enzyme “converged to form quite a compelling package,” Patrick Vallance, head of drug development at Glaxo, said in an interview yesterday. “Sometimes you have to bite the bullet and say, I’m going to study the outcomes that matter.”

More